Delafloxacin meglumine is used to treat bacterial infections, particularly acute bacterial skin and skin structure infections (ABSSSI). It is effective against a broad range of bacteria, including both Gram-positive and Gram-negative pathogens. One of its key advantages is activity against resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA). The compound is formulated for intravenous and oral administration, allowing for flexible treatment options. It achieves high concentrations in skin tissues and maintains effectiveness in acidic environments, making it suitable for infected wound sites. Its use is primarily in hospital or clinical settings where targeted antibiotic therapy is needed for serious infections.